NEW YORK, NY / ACCESSWIRE / August 28, 2020 / Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) resulting from allegations that Fennec may have issued materially misleading business information to the investing public.
On August 11, 2020, Fennec issued a press release announcing receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for the Company’s PEDMARK product, a formulation of sodium thiosulfate for intravenous administration for the ototoxicity associated with cisplatin chemotherapy. The press release stated that “[a]ccording to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.”
On this news, Fennec’s stock price fell $3.51 per share, or 34%, to close at $6.66 per share on August 11, 2020, damaging investors.
Rosen Law Firm is preparing a class-action lawsuit to recover losses suffered by Fennec’s investors. If you purchased shares of Fennec, please visit the firm’s website at http://www.rosenlegal.com/cases-register-1926.html to join the class action. You may also contact Phillip Kim of Rosen Law Firm toll-free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest-ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
SOURCE: The Rosen Law Firm, P.A.
View source version on accesswire.com:
https://www.accesswire.com/603854/EQUITY-ALERT-ROSEN-A-LEADING-AND-TOP-RANKED-LAW-FIRM-Announces-Investigation-of-Securities-Claims-Against-Fennec-Pharmaceuticals-Inc-Encourages-Investors-with-Large-Losses-to-Contact-the-Firm-FENC